# HEM Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hem-pharma

- Industry: Biotechnology
- Headquarters: Pohang, South Korea
- Website: www.hempharma.bio
- Total disclosed funding: $12M
- Latest round: Series A (Aug 14, 2020)
- Investors on record: 7

## About

Founded in 2017 and based in Pohang, South Korea, HEM Pharma operates as a pharmaceutical development and healthcare company that uses microbiomes to analyze and improve human health. As of November 2023, the company is being led by its CEO, Ji Joseph, and Wilhelm Holzapfel, CTO. The firm’s customers include Amway, Phyto Genomics, Enfominance, Samyang, GDK Cosmetics, etc. The company was listed in the KOSDAQ market in November 2024. While in August 2026, Timefolio Asset Management, GVA Asset Management, Mobydick Asset Management, AFW Partners, Skywalk Asset Management, A One Asset Management, IGIS Asset Management, Consus Asset Management, Focus Asset Management, EGA Asset Management, Sunspear Asset Management, Blackpearl Asset Management, Pureun Partners Asset Management, HISSTORY Investment Management, Korea Investment & Securities, NH Hedge Asset Management, WiseMen Asset Management, Life Asset Management, V Asset Management, Korea Asset Investment Securities acquired 1.23 million shares in HEM Pharma at KRW 43,912 for KRW 54 billion, in a PIPE transaction.

## Funding rounds

- Series A, Aug 14, 2020, $12M — WOORI Venture Partners, CJ Investment, Friend Investment Partners, Cosmax BTI, Inc., T Investment, Winvest Venture Capital, Centum Invest

## Investors

- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series A
- CJ Investment (https://capitalatlas.ai/funds/cj-investment) — Series A
- Friend Investment Partners (https://capitalatlas.ai/funds/friend-investment-partners) — Series A
- Cosmax BTI, Inc. — Series A
- T Investment (https://capitalatlas.ai/funds/t-investment) — Series A
- Winvest Venture Capital (https://capitalatlas.ai/funds/winvest-venture-capital) — Series A
- Centum Invest — Series A